Velaglucerase alfa
Top View
- Specialty Medications That Unitypoint at Home Specialty Pharmacy Can Provide Or Facilitate Access to and Is Subject to Change
- Velaglucerase Alfa in the Treatment of Gaucher Disease Type 1: an Update
- Cerezyme® (Imiglucerase), Elelyso® (Taliglucerase Alfa) and VPRIV® (Velaglucerase Alfa) Effective: April 13, 2021
- Velaglucerase Alfa (VPRIV) Reference Number: ERX.SPMN.139 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- Velaglucerase Alfa (VPRIV) Reference Number: CP.PHAR.163 Effective Date: 02/16 Coding Implications Last Review Date: 02/17 Revision Log
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Gaucher's Disease Agents
- Specialty Pharmacy Medications
- Impact of Long-Term Enzyme Replacement Therapy On
- Prior Authorization for Medications
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- Velaglucerase Alfa (VPRIV)
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- VPRIV® (Velaglucerase Alfa)
- Velaglucerase Alfa**
- 129-5-1. Prior Authorization. (A) Any Medical Service May Be Placed by The
- TITLE: Eliglustat Tartrate, Miglustat, Imiglucerase, Velaglucerase Or A
- Elelyso, INN-Taliglucerase Alfa